Biodexa Common Stock from 2010 to 2024

BDRX Stock

4.93 0.13 2.71%

Biodexa Pharmaceticals Common Stock yearly trend continues to be fairly stable with very little volatility. Common Stock is likely to outpace its year average in 2024. During the period from 2010 to 2024, Biodexa Pharmaceticals Common Stock regression line of annual values had r-squared of 0.53 and arithmetic mean of 249,798. View All Fundamentals

Common Stock

First Reported

2014-09-30

Previous Quarter

3.6 M

Current Value

3.6 M

Quarterly Volatility

829.4 K

Yuan Drop

Covid

Check Biodexa Pharmaceticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biodexa Pharmaceticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 268.9 K, Selling General Administrative of 3.9 M or Other Operating Expenses of 11.7 M, as well as many indicators such as Price To Sales Ratio of 4.15, Dividend Yield of 0.0 or PTB Ratio of 0.34. Biodexa financial statements analysis is a perfect complement when working with Biodexa Pharmaceticals Valuation or Volatility modules.

Check out the analysis of Biodexa Pharmaceticals Correlation against competitors.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Latest Biodexa Pharmaceticals' Common Stock Growth Pattern

Below is the plot of the Common Stock of Biodexa Pharmaceticals over the last few years. It is Biodexa Pharmaceticals' Common Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biodexa Pharmaceticals' overall financial position and show how it may be relating to other accounts over time.

Common Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Common Stock

Timeline

Biodexa Common Stock Regression Statistics

	Arithmetic Mean	249,798
	Geometric Mean	11,530
	Coefficient Of Variation	193.87
	Mean Deviation	373,081
	Median	3,000
	Standard Deviation	484,271
	Sample Variance	234.5B
	Range	1.2M
	R-Value	0.73
	Mean Square Error	119.3B
	R-Squared	0.53
	Significance	0
	Slope	78,669
	Total Sum of Squares	3.3T

Biodexa Common Stock History

	2024	1.2 M
	2023	1.2 M
	2022	1.1 M
	2021	98.5 K
	2020	63 K
	2019	23 K

Other Fundumenentals of Biodexa Pharmaceticals

Common Stock Shares Outstanding

Biodexa Pharmaceticals Common Stock component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Intangible Assets	Net Receivables	Short Term Debt	Common Stock	Net Tangible Assets	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Property Plant Equipment	Current Deferred Revenue
Total Assets		0.98	-0.73	0.1	0.67	0.71	0.89	0.94	0.66	-0.38	-0.25	-0.29	0.37	0.34	-0.25	0.23	0.36	-0.17
Total Stockholder Equity	0.98		-0.8	0.09	0.62	0.59	0.92	0.9	0.59	-0.43	-0.3	-0.27	0.35	0.33	-0.3	0.29	0.33	-0.25
Net Debt	-0.73	-0.8		-0.04	-0.29	-0.2	-0.94	-0.55	-0.24	0.4	0.14	0.08	-0.09	-0.08	0.14	-0.14	-0.05	0.06
Retained Earnings	0.1	0.09	-0.04		0.1	0.33	0.02	0.18	0.0	0.83	-0.69	-0.69	0.85	0.83	-0.68	0.63	0.82	-0.61
Accounts Payable	0.67	0.62	-0.29	0.1		0.73	0.52	0.64	0.42	-0.12	-0.35	-0.35	0.46	0.44	-0.35	0.33	0.45	-0.31
Total Liab	0.71	0.59	-0.2	0.33	0.73		0.4	0.79	0.68	0.06	-0.31	-0.38	0.53	0.49	-0.3	0.25	0.53	-0.19
Total Current Assets	0.89	0.92	-0.94	0.02	0.52	0.4		0.71	0.45	-0.45	-0.2	-0.18	0.21	0.18	-0.2	0.2	0.17	-0.12
Intangible Assets	0.94	0.9	-0.55	0.18	0.64	0.79	0.71		0.59	-0.3	-0.29	-0.32	0.44	0.42	-0.28	0.25	0.44	-0.22
Net Receivables	0.66	0.59	-0.24	0.0	0.42	0.68	0.45	0.59		-0.24	0.0	-0.05	0.16	0.14	0.0	-0.03	0.19	0.03
Short Term Debt	-0.38	-0.43	0.4	0.83	-0.12	0.06	-0.45	-0.3	-0.24		-0.43	-0.48	0.59	0.57	-0.42	0.37	0.58	-0.35
Common Stock	-0.25	-0.3	0.14	-0.69	-0.35	-0.31	-0.2	-0.29	0.0	-0.43		0.78	-0.8	-0.84	1.0	-0.96	-0.65	0.87
Net Tangible Assets	-0.29	-0.27	0.08	-0.69	-0.35	-0.38	-0.18	-0.32	-0.05	-0.48	0.78		-0.77	-0.89	0.78	-0.63	-0.61	0.69
Net Invested Capital	0.37	0.35	-0.09	0.85	0.46	0.53	0.21	0.44	0.16	0.59	-0.8	-0.77		0.94	-0.79	0.75	0.96	-0.64
Short Long Term Debt	0.34	0.33	-0.08	0.83	0.44	0.49	0.18	0.42	0.14	0.57	-0.84	-0.89	0.94		-0.83	0.71	0.85	-0.73
Capital Stock	-0.25	-0.3	0.14	-0.68	-0.35	-0.3	-0.2	-0.28	0.0	-0.42	1.0	0.78	-0.79	-0.83		-0.96	-0.64	0.87
Net Working Capital	0.23	0.29	-0.14	0.63	0.33	0.25	0.2	0.25	-0.03	0.37	-0.96	-0.63	0.75	0.71	-0.96		0.64	-0.84
Property Plant Equipment	0.36	0.33	-0.05	0.82	0.45	0.53	0.17	0.44	0.19	0.58	-0.65	-0.61	0.96	0.85	-0.64	0.64		-0.57
Current Deferred Revenue	-0.17	-0.25	0.06	-0.61	-0.31	-0.19	-0.12	-0.22	0.03	-0.35	0.87	0.69	-0.64	-0.73	0.87	-0.84	-0.57

Click cells to compare fundamentals

About Biodexa Pharmaceticals Financial Statements

Biodexa Pharmaceticals investors use historical fundamental indicators, such as Biodexa Pharmaceticals' Common Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biodexa Pharmaceticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Common Stock	1.2 M	1.2 M
Common Stock Shares Outstanding	31.6 K	33.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biodexa Common Stock from 2010 to 2024

Latest Biodexa Pharmaceticals' Common Stock Growth Pattern

Biodexa Common Stock Regression Statistics

Biodexa Common Stock History

Other Fundumenentals of Biodexa Pharmaceticals

Biodexa Pharmaceticals Common Stock component correlations

About Biodexa Pharmaceticals Financial Statements

Also Currently Popular

Additional Tools for Biodexa Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY